M
Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$9.16
-0.21 (-2.24%)
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Monte Rosa Therapeutics Inc (GLUE) Valuation Multiples
Monte Rosa Therapeutics (GLUE) trades at 13.3x sales and 1.9x book value. Its P/B of 1.9x is above its 5-year median of 1.7x. Its forward P/E is 10.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 10.0x |
| Price to sales | 13.3x |
| Price to book | 1.9x |
| PEG | N/A |
| FCF yield | -18.7% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 1.9x | 1.7x | N/A |
Valuation History
Over the 3 of the 5 year ends shown that have a P/S, its P/S ranged from 5.9x in 2024 to 36.8x in 2023.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $15.68 | 10.4x | 4.4x |
| 2024 | $6.94 | 5.9x | 1.9x |
| 2023 | $5.65 | 36.8x | 1.8x |
| 2022 | $7.61 | N/A | 1.4x |
| 2021 | $20.42 | N/A | 2.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About GLUE
What is GLUE's forward P/E ratio?
Monte Rosa Therapeutics has a forward P/E ratio of 10.0x.
Is GLUE stock overvalued?
GNG's valuation label for GLUE is Overvalued.
What is GLUE's price to sales ratio?
Monte Rosa Therapeutics has a price to sales ratio of 13.3x.
GLUE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors